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Cryopreservation of ovarian tissue may be considered in young girls with galactosemia 
Running title: Ovarian cryopreservation and galactosemia 
Abstract  
Purpose: The aim was to describe the first experience with fertility preservation by 
cryopreservation of ovarian tissue (OTC) in pre-pubertal girls with galactosemia and further to 
characterize ovarian follicular morphology and expression of proteins important for ovarian 
function.  
 
Methods: Retrospectively, follicle density was estimated in ovarian cortical tissues from 6 pre-
pubertal girls below the age of 12 years diagnosed with galactosemia and from 31 girls below the 
age of 18 years who had one ovary removed for fertility preservation for other reasons prior to 
gonadotoxic treatment. Additionally, the expression of 4 glycoproteins important for follicle 
development: Anti Müllerian hormone (AMH) pro-mature and C-terminal, growth differentiation 
factor-9 (GDF-9), Bone morphogenetic protein 15 (BMP-15), and pregnancy-associated plasma 
protein A (PAPP-A) were analyzed in 2 galactosemic ovaries (aged 0.9 and 1.7 years) with 
immunohistochemistry and compared to normal age-matched controls.   
 
Results: Girls with galactosemia below the age of 5 years presented with morphological normal 
follicles and follicle densities within the 95% confidence interval (CI) of controls. No follicles were 
detected in the ovary from an 11.7-year-old girl with galactosemia. Expression of AMH, GDF-9, 
BMP-15 and PAPP-A appeared similar in follicles from girls with galactosemia and controls.   
 
Conclusions: These findings suggest that young girls with galactosemia maintain follicles in early 
childhood and fertility cryopreservation may be considered an option in this patient group. The 
pathophysiology of galactosemia leading to an accelerated follicle loss is unknown and it is 
currently unknown to what extend transplanted ovarian tissue can sustain fertility in adult life. 
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Galactosemia is an autosomal recessive genetic disorder in the metabolism of galactose caused by 
impaired activity of galactose-1-phosphate uridyltransferase (GALT). Complete deficiency or 
severely reduced activity of GALT causes classical galactosemia and affects in its most common 
form approximately 1:30,000 to 1:50,000 persons [1–3].  
Girls and women with classic galactosemia have significantly higher serum concentrations of 
follicle stimulating hormone (FSH) and reduced concentrations of Anti Müllerian Hormone (AMH) 
compared to age-matched controls, reflecting a reduced ovarian reserve [4,5]. It has been estimated 
that as many as 80-100% of girls diagnosed with classic galactosemia will experience premature 
ovarian insufficiency (POI) [6–9]. In 47 cases examined absent or abnormal menstrual cycles or 
elevated serum FSH concentrations, have been found in 81% of females ≥15 years, which were 
considered as signs of abnormal ovarian function [6]. In a study of 53 girls with galactosemia, 77% 
experienced POI at a mean age of 13 years [7], suggesting that follicular depletion  is likely to  
initiate already before puberty.    
Though, it has recently been published that almost 30% of women with classic galactosemia and 
POI who actively attempted to conceive actually succeeded within  one year, increasing  to almost 
50% after 2 years of attempting to become pregnant [10]. The prevalence of spontaneously 
conception for women with POI of any cause is only 5-10% [11,12], suggesting that women with 
galactosemia induced POI are more likely to become spontaneous pregnant compared to women 
with other causes of POI. Galactosemic POI may be caused either by an initial reduced pool of 
primordial follicles or by an accelerated depletion of the primordial follicle pool [13]. Aberrant FSH 
activity caused by glycosylation has also been suggested to cause follicle development arrest and 
infertility [14–16]. The three major enzymes important for the conversion of galactose to glucose 
show high ovarian activity in normal females as compared to the testis in males, which may indicate 
an increased synthesis of glycosylated proteins and lipids in the ovary compared to the testis. It has 
been suggested that POI in patients with galactosemia may be due to errors in the synthesis of 
galactose containing glycoproteins and glycolipids in the ovary [17].  
Cryopreservation of ovarian tissue is a fertility preservation option primarily used for girls and 
women diagnosed with a cancer requiring gonadotoxic treatment that may eliminate the ovarian 
pool of follicles and leave the patient menopausal. For pre-pubertal girls and women undergoing 
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urgent gonadotoxic treatment leaving no time for ovarian stimulation and oocyte collection, ovarian 
tissue preservation is the only option available to safeguard fertility. Today, almost 100 babies 
worldwide have been born from transplanted frozen/thawed ovarian tissue [18,19]. The technique 
may also be considered for pre-pubertal girls with a genetic condition that causes an increased risk 
of POI including girls with galactosemia and Turner syndrome [8,14,16,20], though general 
recommendations cannot been given. For galactosemia, this reflects that the speed by which the 
ovarian pool of follicles becomes depleted varies from patient to patient parallel to the phenotypic 
spectrum and GALT mutations. Further, new data suggest that spontaneous pregnancy rates may be 
higher in women with galactosemia than it has previously been suggested [10], which indicates that 
fertility preservation may only be relevant to consider for a subset of girls with galactosemia. 
Unfortunately, women with galactosemia who did and did not spontaneously conceive were similar 
with  respect to age, genotype, age at dietary onset, spontaneous/induced menarche and age at 
menarche, and socio-economic factors [10], and it was  not possible to predict  patients who may 
benefit from early fertility preservation. 
The aim of this study was to present our initial experience with OTC, fertility preservation and 
ovarian characterization in the largest series published until now in girls with galactosemia albeit in 
a very small group of young girls of only 6.   
Materials and methods 
 Patients 
A total of 6 pre-pubertal girls below the age of 12 (mean age 3.8 years ±1.7 (±SEM), range: 0.4—
11.7 years) diagnosed with galactosemia had one entire ovary surgically removed by laparoscopy 
and OTC for fertility preservation at Laboratory of Reproductive Biology, Rigshospitalet, Denmark. 
The control group consisted of 31 girls below the age of 18 years (mean age 13.5 years ±0.7 
(±SEM), range: 1.5—17.9 years) diagnosed with a malignant disease, who had one ovary removed 
for OTC and fertility preservation prior to gonadotoxic treatment [21]. Controls underwent an 
identical surgical procedure and cryopreservation programme at the same department as girls with 
galactosemia. 
All patients were retrospectively included. No surgical complications were reported in connection 
with oophorectomy. Additionally, 2 control ovaries from the archive of the Laboratory of 




Cryopreservation of ovarian tissue 
Ovarian cortex was isolated,  cut into small pieces (Table 1), and processed for cryopreservation as 
previously described [22–24]. One small randomly chosen piece of cortex was fixated in Bouin’s 
solution for histology.  
 
Follicle density 
Tissue was cut in serial sections of 30 or 5 µm for density measurement. The follicle sampling was 
conducted on a Zeiss Axiophot upright microscope. The area of the sections was measured on an 
Olympus BH-2 microscope with VIS version 4.6.1779 software (Visiopharm, Hoersholm, 
Denmark). The follicular density was in 30 µm sections estimated using the mathematical model 
described by Schmidt and colleagues [25]. In brief, this model was based on the fraction of sections 
measured, the height and area of the sections, the mean primordial follicular diameter, and a 
correction factor (α) to account for the possibility to count the same follicle more than once. Since 
the mean diameter of a primordial follicle is 44 µm [26] and the sections were 30 µm there was a 
possibility for counting the same follicle two or three times [25]. In two cases the density was 
measured in 5 µm serial sections as described by McLaughlin and colleagues [27]. In brief, follicles 
were only counted when the nucleolus was observed and the total number of follicles divided by the 
volume of tissue analyzed. Despite these methodological differences the two analysis showed  good 
agreement [27].  
 
Immunohistochemistry 
Tissue was cut in serial sections of 5 µm and prepared for histology using standard methods. 
Antigen was retrieved in citrate-buffer, incubated with monoclonal mouse primary antibodies 
overnight at 4°C, washed in phosphate-buffered saline with Tween20® (PBST), incubated with 
polyclonal mouse-anti-mouse secondary antibody (Dako, Glostrup, Denmark, Cat. no: P0260), 
visualized with DAB+ Novolink™ detection system (Leica Biosystems, Nussloch, Germany, cat. 
no.: RE7230-K) and counterstained with Meyer’s hematoxylin (Amplicon, Odense, Denmark). Anti 
Müllerian hormone (AMH), produced by the granulosa cells of developing pre-antral and antral 
follicles and is increasingly being used to assess the ovarian function was used [28,29]. Two 
antibodies against AMH; one detecting the pro-mature form of AMH (Ansh Lab, Texas, US, 1.7 
µg/ml) and one detecting the active C-terminal of AMH (Ansh Lab, 7.3 µg/ml) [30] was used. 
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Growth differentiation factor-9 (GDF-9) and bone morphogenetic protein 15 (BMP-15)  expressed 
by the oocyte and essential for follicular development beyond the primary follicle stage [31,32] was 
used (Ansh Lab, 5.5 µg/ml and 6.8 µg/ml, respectively). Pregnancy associated plasma protein A 
(PAPP-A) suggested to be involved in the regulation of the steroidogenesis in human antral follicles 
[33] was used (PACI-D8-mlgG2a, 7.0 µg/ml).  
 
Ethical Considerations 
In Denmark OTC is by law offered exclusively to girls and women who are at risk of iatrogen 
induced follicle loss or have a genetic disease that poses a risk of destroying the ovarian function. 
Based on patient age, general health conditions, the risk of inducing or achieving POI and other 
factors the doctor decides whether OTC is offered or not. The procedure is performed in the public 
health care system and is free of costs for the patient in all aspects including OTC, storage, 
transplantation and potential assisted reproduction procedures.  
All patients were below the age of 18 years were represented by their parents or guardians who 
were counselled by a doctor and received information about the procedure including the current 
results and the outlook for providing fertility in the future. The parents were informed about their 
daughters’ personal risk, the fertility preservation options - for pre-pubertal OTC is the only 
available treatment, and that this procedure in young girls is experimental and there will be no 
guarantee for subsequent restoration of fertility. It was the parents or guardians who decided 
whether they want to accept the offer for OTC. In this group of galactosemic patients OTC at an 
early age was recommended due to the rapid follicle decline associated with the disease, the speed 
of which for individual patients is currently unknown. As all participating patients were underage, 
their parents gave their informed consent on behalf of their daughters to participate according to 




Microsoft Excel version 14.6.1 was used to analyze the data. Data on follicle densities in girls 
below the age of 18 years who have received no medical treatment before oophorectomy has 
previously been compared to the densities in girls who had received chemotherapy before 
ovariectomy and been published by El Issaoui and colleagues [21]. The quadratic model presented 
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by El Issaoui and colleagues [21] was useful for comparing the treated and untreated groups for that 
study, but is not useful for age-related normative predictions due to residuals being non-normally 
distributed. The same data was used to derive a more suitable model: log10(density +1) 
=a+bx^(0.5)ln(x) with parameter values a = 3.067 (95% confidence interval (CI) 2.30 —  3.83) and 
b = -0.13 (95% CI -0.21 — -0.05). This model has more normally distributed residuals (84% of a 
perfect Gaussian distribution).  
 
Results 
All 5 girls with galactosemia below the age of 5 years presented with a mean follicle density ±SEM 
of 1,130 ±420 follicles per mm3, which were within the 95% CI of the control group (Fig. 1). The 
mean follicle density ±SEM in the control group was 333 ±131. In contrast, no follicles were 
detected in the ovarian biopsy obtained from the 11-year-old girl. The exact follicle densities 
together with the number and size of the cryopreserved ovarian cortex pieces and patient genotype 
are shown in table 1. All follicles were primordial follicles. 
  
The glyco-proteins important for follicular health: Pro-mature AMH, C-terminal AMH, GDF-9, 
BMP-15, and PAPP-A were present in follicles from 2 girls with galactosemia aged 0.9 and 1.7 
years and in age-matched normal control ovaries. Due to limited material controls was performed in 
normal ovaries of two girls aged 0.6 years and 19 days (Fig. 2). 
 
Histological sections of the ovarian cortex from girls with galactosemia containing follicles showed 
morphological normal primordial follicles, though no growing follicles were observed (Fig. 3). A 
fraction of the follicles in the 1.7-year-old ovary appeared to have lost the oocyte nucleus and be in 
a process of atresia.   
 
Discussion 
This is to our knowledge the first study to evaluate the possibility of OTC and fertility preservation 
in young girls with the rare genetic disease galactosemia. Further, follicular density and 
immunohistochemical expression of oocyte and granulosa cell expressed proteins were evaluated. 
The study only includes a total of 6 patients with galactosemia and is obviously limited in size but 
is nonetheless the largest and only study to evaluate the ovarian fertility potential. 
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The follicle density in ovarian cortex was evaluated in 6 pre-pubertal girls diagnosed with 
galactosemia and compared to the density in a group of normal ovaries below the age of 18 years. 
The control ovaries are older (mean age 13.5 years old) compared to ovaries with galactosemia 
(mean age 3.8 years old), which is a limitation to the study.  All 5 ovaries below the age of 5 years 
presented with follicle densities within the 95% CI of normal ovaries and with a normal follicular 
morphology. In contrast, the girl aged 11.7 years presented with no follicles, suggesting that in this 
cohort follicles are maintained in the first years of life but are at risk of undergoing an accelerated 
loss  in early childhood [6–9].  
In 2 cases sufficient ovarian tissue for IHC analysis was available. Glycosylated proteins important 
for normal follicle development were detected in follicles of these two cases and in normal age-
matched follicles, suggesting that these young girls may have normal follicles. Using the Santa Cruz 
anti-AMH antibody Weenen and colleagues didn’t observe AMH expression in human primordial 
follicles [34], which is in contrast to the present findings were AMH was detected in both 
galactosemic and control ovaries. We used highly specific anti-AMH antibodies provided by Ansh 
Laboratories and have detected AMH in primordial follicles with several AMH specific antibodies 
detecting different epitopes. The discrepancy between these studies may be due to the antibodies 
used. GDF-9 is suggested to be essential for normal folliculogenesis and have in several studies 
shown to be expressed by the oocyte and the granulosa cells beyond the primary, but not in 
primordial follicles [16,35–37]. Though, gene expression of Gdf-9 have been detected in murine 
germ cells and primordial follicles already during embryogenesis [38] and in vitro studies have 
shown that GDF-9 and BMP-15 promote primordial follicle formation in both hamster and human 
ovary [39,40]. In the human fetal ovary both GDF-9 and BMP-15 mRNA have been detected with 
marked increase in expression across gestation [41] and GDF-9  proteins have been detected in 
human fetal germ cells from the initiation of oocyte nest breakdown (gestational week 8) to the 
primordial follicle formation in week 20 [41]. Further, in adult human ovaries AMH, GDF-9 and 
BMP-15 mRNA have also been detected in primordial and early primary follicles with increasing 
expression with follicle size [42] and GDF-9 and BMP-15 proteins have been detected in human 
primordial follicles [43], supporting the present findings of AMH, GDF-9, and BMP-15 being 
present in human primordial follicles. The presence of PAPP-A in human primordial and late 
primary follicles has been reported  [44] and the present finding support the literature. 
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 Taken together, considering the expression of the 4 evaluated proteins there is no obvious 
differences between normal and galactosemic ovaries, which is supported by the fact that several 
women with galactosemia actually have conceived spontaneously.   
However, this study does not reveal whether these follicles, if subsequently transplanted, will be 
functional and provide fertility. Further, we cannot state whether these observations are 
representable for young girls with galactosemia. The present study does not define an age limit 
beyond which the pool of ovarian follicles becomes too low to consider fertility preservation. 
However, the pool of follicles appears gradually to decline very early in life and if fertility 
preservation is considered it should be performed in early childhood in order to save as large a 
cohort of primordial follicles as possible. 
Previous studies have found significantly lower serum AMH levels in girls and women with 
galactosemia compared to age-matched controls [4,5], which are expected since the total number of 
follicles are  reduced. In addition the number of growing follicles – which especially contribute to 
the circulating levels of AMH – appear also to be reduced [29]. Low AMH levels in girls with 
galactosemia are therefore expected. The present study demonstrates the presence of both the pro-
mature AMH and the active C-terminal AMH in follicles of 2 girls with galactosemia, suggesting 
that in these two cases AMH is synthesized to some extent.  
The present findings confirm and extend the observation by Levy and colleagues who, in a 5-day-
old infant with galactosemia who died, found histologically normal ovaries with normal follicle 
development [45].  Histological studies in adolescents with galactosemia have found a remarkably 
altered ovarian morphology and reduced or absent follicle number in girls aged 16—17 years [46–
48], indicating that the ovarian function may be compromised already at puberty, which corroborate 
with the observation in a 11.7-year-old girl of the present study.  
Despite delayed pubertal development, amenorrhea, and POI in most women with galactosemia, a 
few manage to conceive - worldwide around 50 pregnancies have been described [2,14,15]. 
Moreover, a recent study suggest that pregnancy chances in women with galactosemia may be 
higher than previously reported [10]. These data suggest that almost 50% of women with 
galactosemia and POI who attempt to conceive actually do succeed  within two years, though a 
considerable miscarriage rate (30%) was observed [10]. Women who conceived did not differ from 
women who could not conceive with respect to patient characteristics  [10], which makes it difficult 
9 
 
to determine who potentially could benefit from early fertility preservation. However, these findings 
clarify that galactosemia is not incompatible with caring a pregnancy.  
In Denmark, ovarian tissue fertility preservation is offered to girls and women who run the risk of 
iatrogen induced POI or have a genetic disease with the risk of POI. Case reports from Denmark 
and France have demonstrated that puberty can be induced in girls who  had OTC before puberty  (9 
and 10 years of age) [49,50]. These reports indicate that frozen/thawed transplanted ovarian tissue 
can work properly and even a small fraction of the cryopreserved tissue is sufficient to induce 
puberty. In case of a later pregnancy-wish additional cortex pieces can be transplanted. Moreover, a 
healthy child has just been born in England from pre-pubertal cryopreserved ovarian tissue auto-
transplanted in Denmark, demonstrating that fertility can be restored from ovarian tissue preserved 
before puberty (Mathwes et al., 2018, in press). Irrespective of diagnosis, there are currently no 
reports on whether OTC at very early ages as the present study (mean age 3.8 years) actually will 
reactivate and undertake ovarian function including fertility when transplanted. Many of these girls 
may not need the tissue for fertility purposes before after 20 years of storage or more, why more 
years needs to elapse before these patients may return for transplantation. However, a recent follow-
up study evaluating complication in connection with laparoscopically removal  and transplantation 
of ovarian tissue found the procedure to have a low risk of complications with 0.2% complications 
occurred (3 in 1302 procedures)  irrespective of age [51]. 
Even though cryopreservation is a valid method for fertility preservation [18,19] it is not known for 
how long frozen/thawed ovarian tissue will function in women with galactosemia after 
transplantation. Women with other diagnoses than galactosemia have shown ovarian activity for 
more than eight years [52]. There is a risk that the underlying disease will affect the graft longevity 
and the period of ovarian function following transplantation in patients with galactosemia cannot be 
estimated. All though the function of the tissue could be short because of the possible negative 
influence of the metabolic situation in galactosemia, 6—12 months of function may be sufficient to 
mature follicles, which can then be used in connection with assisted reproduction. If the ovarian 
tissue survivals longer, assisted reproduction may not even be necessary, though most women with 
ovarian transplants will require assisted reproduction to conceive. Alternatively, in vitro methods to 
mature oocytes from cortical tissue may be developed and thereby provide mature oocytes to be 
used for assisted reproduction. However, actual experience with transplantation to galactosemic 
patients will have to await for these girls reach a normal childbearing age.  
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Taken together, these findings suggest that girls with galactosemia may have ovarian follicles in the 
first years of life, OTC and fertility preservation of ovarian tissue may be considered an 
experimental treatment option. If ovarian preservation is considered it is suggested to preserve early 
in life in order to preserve as large a pool of ovarian follicles as possible, especially because the 
speed by which the follicle number decline in girls with galactosemia has only just started to be 
outlined. However, the larger the follicle reserve the greater the chance of a successful outcome. It 
is important to note that OTC in this particular group of patients is experimental and the potential 
benefit of the method is unknown and needs to await actual transplantation of frozen/thawed tissue.  
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Fig. 1: Follicular density (follicles/mm3) in ovarian cortex in 6 girls with galactosemia (circles) and 
in normal control ovaries (triangles). The lines illustrate the predicted follicular density and the 95% 
confidence intervals (CI). Girls with galactosemia below the age of 5 years have follicle densities 
similar to controls, whereas the girls with galactosemia aged 11.7 years had no follicles.      
Fig. 2: Immunohistochemical detection of pro-mature and C-terminal AMH, GDF-9, BMP-15, and 
PAPP-A in ovarian cortex from two girls with galactosemia (aged 0.9 and 1.7 years old), together 
with controls (0.6 years and 19 days old). The evaluated proteins important for follicular health 
were detected both in follicles with galactosemia and in normal controls.    
Fig. 3: Ovarian cortex from 5 girls below the age of 5 years with galactosemia had morphological 
normal primordial follicles, though no growing follicles were observed (A-E). A fraction of the 
follicles in (C) appeared to have lost the oocyte nucleus and be in a process of atresia. An age-
matched control ovary (0.6 years old) had morphologically normal follicles (F).   
